Health Condition 1: A488- Other specified bacterial diseases
Conditions
Interventions
Intervention1: Platelet rich fibrin: autologous, derived from patients own blood, centriguged at 3000 rpm for 10 min, no added agents
Control Intervention1: Human recombinant platelet derived growth f
Sponsors
Amruta Joshi
Eligibility
Inclusion criteria
Inclusion criteria: 2. Subjects diagnosed with chronic periodontitis based on American Academy of Periodontology (AAP) classification 1999. 3. Atleast one interproximal probing depth (IPD) >=5 mm, 4 weeks after Phase I therapy. 4. Presence of 2 or 3 walled intrabony defect (IBD) >=3 mm which was measured as the distance from the interproximal alveolar crest to the base of the defect on an intraoral periapical radiograph with a 1 mm grid.
Exclusion criteria
Exclusion criteria: 1. Subjects diagnosed with Aggressive Periodontitis. 2. Subjects having unacceptable oral hygiene [Plaque index51 (PI) and Modified gingival index52 (MGI) >1] after re-evaluation of Phase I therapy. 3. Presence of pulpal or periapical involvement on qualifying teeth. 4. Endodontically treated teeth or any tooth with endo perio lesion. 5. Poor, questionable or hopeless prognosis of qualifying teeth. 6. Subjects with chronic periodontitis who have received any form of periodontal therapy, surgical or non-surgical within past 6 months. 7. Subjects who have received orthodontic treatment in past 6months. 8. Subjects with deleterious habits including tobacco chewing, smoking. 9. Subjects with known systemic illness. 10. Subjects who have received antibiotic therapy within past 6months 11. Subjects on anti-inflammatory drug regimen since past 6 months. 12. Subjects suffering from bleeding disorders. 13. Pregnant women and lactating mothers. 14. Physically and mentally challenged subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To biochemically evaluate and compare the release profile of platelet derived growth factor BB (PDGF-BB) in gingival crevicular fluid (GCF) collected from intrabony defects treated with platelet rich fibrin (PRF) and collagen membrane (CM) containing recombinant human Platelet derived growth factor-BB (rhPDGF-BB).Timepoint: Day 3, Day 7, Day 14, Day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| To biochemically evaluate and compare alkaline phosphatase (ALP) levels in GCF collected on days 3 and 30 from intrabony defect sites treated with PRF membrane and CM containing rhPDGF-BB. To clinically evaluate and compare wound healing on days 7 and 14 at sites treated with PRF membrane and CM containing rhPDGF-BB. Timepoint: 3rd and 30th day 7th and 14th day | — |
Countries
India
Contacts
Public ContactAmruta Joshi
MGM dental college and hospital, Navi Mumbai
Outcome results
None listed